Project title – Family
Focused HIV Prevention, Care and Treatment (FFHPCT) Services
Demand Creation for Cervical Cancer Screening among Women
Living with HIV in Ethiopia
Cervical cancer in Ethiopia
Cervical cancer
incidence and mortality has been drastically reduced in high resource countries
during the last decades. This can be largely attributed to the implementation
of screening programs for the detection of precancerous lesions and HPV and
improved therapy. Yet in low- and middle income countries where access to such
measures is limited, cervical cancer remains a significant health problem. The
vast majority of an estimated number of 311.000 cervical cancer deaths
worldwide occur in less developed regions.
In Ethiopia, where
almost 6.300 new cases are diagnosed annually, about 4.884 women die from
cervical cancer each year. This makes cervical cancer the second-most common
cancer in the country, and the second-most deadly cancer among Ethiopian women.
One of the most
important prognostic factors is stage at diagnosis, linking early-stage
diagnosis with better chances of survival; still most cervical cancer patients
present at advanced stages in Ethiopia. Studies examining predictors of late
and advanced stage presentation of cervical cancer patients in low- and
middle-income countries have been scarce. The relationship between HIV-infection
and cervical cancer and the question of whether HIV-infection leads to more
advanced cancer stages is discussed controversially. The timespan between
symptom onset and diagnosis has been associated with stage at diagnosis, but
other studies could not confirm this. However, these studies were conducted in
high-income countries where time to diagnosis is considerably shorter. It is
unclear whether these results likewise apply to low-income countries such as
Ethiopia, where time to diagnosis is long and patients present at advanced
stages. Tragically, in a previous study of a hospital cohort of 1.059 cervical
cancer patients receiving oncologic treatment in Addis Ababa, Ethiopia, we
found long periods of time between diagnosis and the beginning of cancer treatment.
This led to stage-migration and thus decreased chances of survival
Studies also
shows that HIV-infection was associated with more advanced cancer stages at
time of diagnosis compared to patients with a negative or unknown HIV-status.
The association of HIV and HPV is well-known, and previous studies repeatedly
linked HIV-infection with a higher prevalence, incidence and persistence of
HPV-infection and its progression into precancerous lesions (especially for
patients with low CD4 cell counts). However, the association between HIV and
invasive cervical cancer is less clear. Published data indicate a 1.6 to 2.4
increased risk of developing invasive cervical cancer for HIV-positive women.
The effect of sero-prevalence of HIV on cancer stage at time of diagnosis in
comparable settings is similarly hard to establish.
Cervical
cancer screening enables the detection of abnormal cervical cells, including
precancerous cervical lesions, as well as early stage cervical cancers. Routine
cervical screening has been shown to reduce both the incidence and mortality of
the disease. However, over 80% of invasive cervical cancers worldwide occur in
developing countries, largely as a result of the challenges in establishing
effective screening programs. The World Health Organization estimates that only
about 5% of women have been screened for cervical cancer in resource-poor
countries, compared to 40–50% in the developed world. In Sub Sharan Africa,
there have been efforts to improve awareness and the availability of cervical
screening services. However, the coverage still remains low and the incidence
and mortality rates associated with the disease are high in this region.
Ethiopia is one of the Sub-Saharan countries in
which cervical cancer is the second most frequently diagnosed cancer among
women, next to breast cancer. The WHO 2012 report showed that the estimated
incidence of cervical cancer in Ethiopia was 17.3%, with a mortality of 16.5%.
The age-standardized incidence rate of 26.4 per 100, 000 women was estimated in
2012. Studies have shown that the practice of screening is followed by
knowledge of cervical cancer and screening. However, in Ethiopia, the overall
coverage of cervical cancer screening was found to be 0.8% according to the ICO
Information Centre on HPV and Cancer 2017. A study from the Northeast part of
the country showed that only 57.7% of women had ever heard of cervical cancer,
and 51.9% had sufficient knowledge of the disease. Nevertheless, 11% had
undergone cervical screening at least once in their lifetime. In Mekelle, in
the north of the country, among eligible women, 19.8% had been screened for
cervical cancer, while in the northwest part of Ethiopia, a study showed that
only 14.7% of women with knowledge of cervical cancer screening had undergone
cervical cancer screening. The study also found that knowledge of the risk
factors, symptoms and preventive options regarding cervical cancer were very
low; a study in Addis Ababa found that only 6.5% of the respondents had
experienced a Pap smear test.
As it is well known, NNPWE in partnership with
Project Hope has been engaged on creating awareness about cervical cancer and
creating demand for screening among women living with HIV and the community.
Promising results have been registered so far. Thus, NNPWE would like to extend
its activities to additional 4 associations and strengthen the on-going demand
creation activities through its associations.
General objective – The general objective of this service level
agreement (FSLA) is to continue and expand the awareness creation activities on
cervical cancer screening and treatment among WLHIV who are members of NNPWE
WPLHIV association at and other women focused organizations (CBOs, CSO, etc…)
in CHCT target areas and provide referral services to HFs for eligible and
consenting WLHIVs.
Specific objectives
–
To create
awareness and knowledge among WLHIV about cervical cancer and its treatment through
demand creation materials
–
To build
the capacity for Women PLHIV associations and other actors to do cervical
Cancer demand creation
–
To initiate WLHIV
to screen for cervical cancer and to facilitate referral linkage of eligible
and consenting WLHIV for cervical cancer screening to service providing health
facilities
Activities and intervention strategies
–
Facilitate
sensitization events on Cx Ca
–
Recruit and train
additional volunteer women among WLHIV
Associations
–
Deploy volunteers
to create awareness about cx ca among WLHIV associations and their community
–
Prepare and
distribute various demand creation materials
–
Work closely with
USAID FFHPCT activity implementing LIPs.
–
Monitor and
evaluate the progress of the activity
periodically
Major activities performed so far
–
Cervical
cancer demand creation strategy and material development – NNPWE in partnership
with Project HOPE has developed brochure, poster, radio spot and TV spot. The
materials were distributed among NNPWE’s associations and USAID Local
Implementing Partners (LIPS) to create awareness among women living with HIV
and other community members to understand about cervical cancer and to get
screening services. The radio spot has been on air for about 20 days on EBC
(national radio station).
–
Capacity
building for demand creation and referral of WLHIV for cervical cancer
screening to services providing health facilities – NNPWE has trained 39
volunteers among 12 associations and deployed to create awareness among their
association members and their community. So far, 2,892women are reached with
the message whereas 489women were screened at various government based health
facilities.
–
Conduct
cervical cancer demand creation at community level – NNPWE has been
creating an orientation session about cervical cancer to different local
non-governmental organizations, community based organizations and women
associations, non-women specific PLHIV associations and grass root organization
as well as government offices to use their platforms to cascade the message and
facilitate the screening for cervical cancer among women.